Marker Therapeutics, Inc.

Monthly Archives: September 2014

TapImmune CEO Provides Update on Corporate Activity and Progression of Clinical Programs

I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.
Read More

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer

All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes.
Read More

TapImmune Inc to Present at SeeThruEquity Microcap Conference

Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday September 11th at the Convene Times Square, New York City.
Read More

TapImmune Inc to Present at 16th Annual Rodman & Renshaw Healthcare Conference

Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman &
Read More